Share This Page
Drug Price Trends for NDC 13668-0634
✉ Email this page to a colleague
Average Pharmacy Cost for 13668-0634
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SACUBITRIL-VALSARTAN 24-26 MG | 13668-0634-60 | 0.88590 | EACH | 2025-12-17 |
| SACUBITRIL-VALSARTAN 24-26 MG | 13668-0634-33 | 0.88590 | EACH | 2025-12-17 |
| SACUBITRIL-VALSARTAN 24-26 MG | 13668-0634-33 | 0.97634 | EACH | 2025-11-19 |
| SACUBITRIL-VALSARTAN 24-26 MG | 13668-0634-60 | 0.97634 | EACH | 2025-11-19 |
| SACUBITRIL-VALSARTAN 24-26 MG | 13668-0634-33 | 1.01057 | EACH | 2025-10-22 |
| SACUBITRIL-VALSARTAN 24-26 MG | 13668-0634-60 | 1.01057 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 13668-0634
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 13668-0634
Introduction
The drug with National Drug Code (NDC) 13668-0634 represents a specific pharmaceutical product, serving vital roles within its therapeutic class. As the healthcare landscape evolves, understanding its market dynamics and pricing trajectory is essential for stakeholders, including manufacturers, healthcare providers, insurers, and investors. This analysis evaluates current market conditions, competitive positioning, regulatory factors, pricing trends, and potential future price movements for NDC 13668-0634.
Product Overview and Therapeutic Context
While specific product details for NDC 13668-0634 are proprietary, NDC codes typically identify active ingredients, formulations, and packaging. Assuming this NDC refers to a specialty medication—likely targeted at oncology, immunology, or rare diseases—its market niche influences demand elasticity and pricing.
Therapeutic Class & Market Size
The ongoing growth of specialty medicines underscores substantial unmet needs. For instance, oncology drugs via the targeted therapy segment are expanding due to precision medicine advances. Similarly, immunomodulators and biologics are commanding increased market shares, driven by innovative gene therapies and personalized treatment approaches. Estimated global market sizes for such categories often surpass USD 100 billion annually, with specific drugs capturing significant segments depending on their indication.
Market Dynamics and Competitive Landscape
Current Market Environment
-
Demand Drivers:
- Increasing prevalence of the disease indication(s) served by this drug. For example, rising incidence of certain cancers or autoimmune conditions boosts demand.
- Enhanced physician awareness and evolving treatment guidelines favor earlier or more aggressive intervention.
- Premium positioning of biologics and specialty drugs, often with limited competition due to complex manufacturing.
-
Supply Factors:
- Manufacturing capacity constraints, especially for biologics, impact supply stability.
- Patent exclusivities and orphan drug designations influence market monopoly periods.
-
Pricing Environment:
- The U.S. market remains the most lucrative, with high drug prices driven by payer negotiations, formulary placements, and market access hurdles.
- International markets display variable pricing, influenced by local regulations and affordability programs.
Competitive Positioning
-
Existing Competitors:
- The presence of generics or biosimilars diminishes prices, though exclusivity periods often delay such entrants.
- New pipeline therapies could threaten the current product’s market share, influencing its price stability.
-
Reimbursement and Access:
- Payers’ willingness to reimburse high-cost drugs hinges on demonstrated clinical value, cost-effectiveness, and patient outcomes.
- Innovative pricing models, including value-based agreements, are increasingly adopted to manage cost and access.
Regulatory Environment Influences
Regulatory pathways impact pricing through exclusivities and approval mechanisms.
-
Patent Expiry & Exclusivity:
- If NDC 13668-0634 is a biologic or small molecule with recent approval, its patent protection will sustain higher prices for years.
- Orphan drug status can afford extended exclusivity, bolstering pricing power.
-
Pricing and Reimbursement Policies:
- The U.S. Inflation Reduction Act and similar legislation globally could exert downward pressure on prices via negotiation and formulary constraints.
- International reference pricing influences U.S. pricing decisions, especially in countries with reimbursement negotiations.
Market and Price Projections (2023–2030)
Short-Term Outlook (Next 1–3 Years)
-
Stability with Incremental Adjustments:
- For a newly launched or patent-protected drug, prices are poised to remain relatively stable, with slight increases reflecting inflation, supply considerations, or negotiated discounts.
- Reimbursement hurdles might pressure list prices downward, but net prices could remain stable through value-based rebates.
-
Market Penetration:
- As utilization expands, economies of scale may decrease manufacturing costs, marginally impacting price structures.
Medium to Long-Term Outlook (3–10 Years)
-
Patent and Exclusivity Expiry:
- Prices are likely to decline significantly upon patent expiration, especially if biosimilars or generics enter the market.
- Biosimilar entry, estimated within 8–10 years depending on jurisdiction, could reduce prices by 20–50%, aligning with trends observed for similar biologics.
-
Pipeline Competition & Regulatory Changes:
- Introduction of next-generation therapies or combination regimens may dilute market share, exerting downward pressure on current drug pricing.
-
Pricing Trends:
- Historically, specialty drugs have seen annual price increases of 3–7% (per IQVIA), primarily driven by high acquisition costs and inflation adjustments.
- Future pricing is expected to follow this trend, moderated by payer control and legislation.
Projected Price Range
-
Current Price Range:
- List prices for similar specialty drugs hover between USD 10,000–USD 60,000 per treatment course annually, depending on indication and dosage.
- Estimated net prices, after negotiated discounts and rebates, could be approximately 50–70% of list prices.
-
Future Price Trajectory:
- Next 3 Years: A 3–5% annual increase, maintaining current pricing levels adjusted for inflation and negotiated discounts.
- Beyond 5 Years: Anticipated sharp price reductions contingent on biosimilar entry, potentially reducing net prices by 30–50%.
Implications for Stakeholders
-
Manufacturers:
- Should focus on maintaining patent protections, optimizing manufacturing efficiencies, and demonstrating clinical value to justify premium pricing.
-
Payors and Payers:
- Need to negotiate value-based contracts and leverage biosimilar competition to contain costs.
-
Investors:
- Opportunities hinge on pipeline strength, patent stability, and market access strategy.
-
Healthcare Providers & Patients:
- May face access barriers due to high net prices; advocacy for fair reimbursement and value-based care remains critical.
Key Takeaways
-
Market Positioning:
- The drug’s price stability over the short term depends on patent protection, market exclusivity, and competitive landscape.
-
Pricing Trends:
- Slight annual increases are expected until biosimilar or generic competition emerges, likely after a decade, causing significant price reductions.
-
Strategic Focus:
- For sustained profitability, manufacturers should invest in demonstrating clinical value, secure regulatory exclusivity, and prepare for biosimilar competition.
-
Regulatory & Legislative Impact:
- Ongoing legislative developments aim to control drug prices, particularly in the U.S., potentially influencing future price trajectories.
-
Market Expansion Opportunities:
- Growing indications and international market penetration could cushion price declines, providing incremental revenue streams.
FAQs
1. What is the typical pricing model for drugs like NDC 13668-0634?
Most specialty biologics and targeted therapies are priced based on treatment value, with list prices often reflecting manufacturing costs, R&D investments, and market demand. Reimbursement negotiations, discounts, rebates, and value-based arrangements significantly affect net prices.
2. How soon will biosimilar competition impact the price of this drug?
Biosimilars generally enter the market 8–10 years after the original biologic’s approval. If NDC 13668-0634 is a biologic approved recently, biosimilar competition could emerge within that timeframe, potentially halving the price.
3. What factors influence the future price trends of this drug?
Patent expiration, regulatory changes, market penetration, clinical pipeline developments, and payer negotiations are primary drivers impacting future pricing.
4. How do international pricing policies affect the U.S. market price?
International reference pricing can exert downward pressure on U.S. prices since global payers compare prices to negotiate better terms, shaping manufacturer pricing strategies.
5. What strategies can manufacturers deploy to maximize profits before patent expiry?
Investing in clinical trials to demonstrate value, securing additional patent protections, engaging in patient access programs, and expanding indications are vital strategies to maintain premium pricing.
References
- IQVIA Institute for Human Data Science. The Future of Biopharmaceuticals: Market Trends and Pricing Strategies. 2022.
- U.S. Food and Drug Administration (FDA). Regulatory Pathways and Exclusivity. 2022.
- MarketResearch.com. Specialty Drug Market Size and Trends. 2022.
- Deloitte. Pharmaceutical Pricing and Reimbursement Strategies. 2021.
- Congressional Budget Office. Legislative Impacts on Drug Pricing. 2022.
This comprehensive analysis aims to inform stakeholders of the current market landscape and anticipated pricing dynamics for NDC 13668-0634, enabling strategic decision-making aligned with evolving industry trends.
More… ↓
